196 related articles for article (PubMed ID: 19533687)
1. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.
Uneda S; Toi H; Tsujie T; Tsujie M; Harada N; Tsai H; Seon BK
Int J Cancer; 2009 Sep; 125(6):1446-53. PubMed ID: 19533687
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.
Tsujie M; Tsujie T; Toi H; Uneda S; Shiozaki K; Tsai H; Seon BK
Int J Cancer; 2008 May; 122(10):2266-73. PubMed ID: 18224682
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
4. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
[TBL] [Abstract][Full Text] [Related]
5. Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).
Toi H; Tsujie M; Haruta Y; Fujita K; Duzen J; Seon BK
Int J Cancer; 2015 Jan; 136(2):452-61. PubMed ID: 24866768
[TBL] [Abstract][Full Text] [Related]
6. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
Tsujie M; Uneda S; Tsai H; Seon BK
Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
[TBL] [Abstract][Full Text] [Related]
7. Endoglin-targeted cancer therapy.
Seon BK; Haba A; Matsuno F; Takahashi N; Tsujie M; She X; Harada N; Uneda S; Tsujie T; Toi H; Tsai H; Haruta Y
Curr Drug Deliv; 2011 Jan; 8(1):135-43. PubMed ID: 21034418
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
Tabata M; Kondo M; Haruta Y; Seon BK
Int J Cancer; 1999 Aug; 82(5):737-42. PubMed ID: 10417773
[TBL] [Abstract][Full Text] [Related]
9. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK
Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and metastasis marker of human tumors.
Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
[TBL] [Abstract][Full Text] [Related]
12. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.
Shiozaki K; Harada N; Greco WR; Haba A; Uneda S; Tsai H; Seon BK
Cancer Immunol Immunother; 2006 Feb; 55(2):140-50. PubMed ID: 15856228
[TBL] [Abstract][Full Text] [Related]
14. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
She X; Matsuno F; Harada N; Tsai H; Seon BK
Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity.
Bonfil RD; Vinyals A; Bustuoabad OD; Llorens A; Benavides FJ; Gonzalez-Garrigues M; Fabra A
Int J Cancer; 1994 Jul; 58(2):233-9. PubMed ID: 7517919
[TBL] [Abstract][Full Text] [Related]
16. Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.
Paauwe M; Heijkants RC; Oudt CH; van Pelt GW; Cui C; Theuer CP; Hardwick JC; Sier CF; Hawinkels LJ
Oncogene; 2016 Aug; 35(31):4069-79. PubMed ID: 26804178
[TBL] [Abstract][Full Text] [Related]
17. Identification of an invasion and tumor-suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma.
Wong VC; Chan PL; Bernabeu C; Law S; Wang LD; Li JL; Tsao SW; Srivastava G; Lung ML
Int J Cancer; 2008 Dec; 123(12):2816-23. PubMed ID: 18798555
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis for radioimmunotherapy with a
Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
[TBL] [Abstract][Full Text] [Related]
19. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.
Fonsatti E; Nicolay HJ; Altomonte M; Covre A; Maio M
Cardiovasc Res; 2010 Apr; 86(1):12-9. PubMed ID: 19812043
[TBL] [Abstract][Full Text] [Related]
20. Is it the primetime for endoglin (CD105) in the clinical setting?
Maio M; Altomonte M; Fonsatti E
Cardiovasc Res; 2006 Mar; 69(4):781-3. PubMed ID: 16448632
[No Abstract] [Full Text] [Related]
[Next] [New Search]
